- Apr 2, 2009
- 5,171
- 13,288
- 67
Lead (and lengthy) article in today's Washington Post Business section.
[SIZE=+0]Anemia drug made billions, but at what cost? [/SIZE]
[SIZE=+0]http://www.washingtonpost.com/busin...at-what-cost/2012/07/19/gJQAX5yqwW_print.html
http://www.washingtonpost.com/busin...12/07/19/gJQAX5yqwW_story.html?wpisrc=al_excl
[/SIZE]
Some excerpts
[SIZE=+0]Anemia drug made billions, but at what cost? [/SIZE]
[SIZE=+0]http://www.washingtonpost.com/busin...at-what-cost/2012/07/19/gJQAX5yqwW_print.html
http://www.washingtonpost.com/busin...12/07/19/gJQAX5yqwW_story.html?wpisrc=al_excl
[/SIZE]
Some excerpts
For years, a trio of anemia drugs known as Epogen, Procrit and Aranesp ranked among the best-selling prescription drugs in the United States, generating more than $8 billion a year for two companies, Amgen and Johnson & Johnson.
The trouble, as a growing body of research has shown, is that for about two decades, the benefits of the drug including life satisfaction and happiness according to the FDA-approved label were wildly overstated, and potentially lethal side effects, such as cancer and strokes, were overlooked.
"It was just so easy to do you put this stuff in the patients arm, and you made thousands of dollars, said Charles Bennett, endowed chair at the Medication Safety and Efficacy Center of Economic Excellence at the University of South Carolina and one of the critics of the use of the drug in cancer patients. An oncologist could make anywhere from $100,000 to $300,000 a year from this alone. And all the while they were told that it was good for the patient.
By 1994, the drugs label, approved by the FDA, advertised a range of benefits: statistically significant improvements for . . . health, sex life, well-being, psychological effect, life satisfaction, and happiness.
With FDA approval, Johnson & Johnson halted the study, never finding evidence of clear dangers. But as Medicare researchers would later remark, the patients taking the drugs appeared more likely to die than those taking the placebo.
Amgen, which already had a sizable in-house lobbying effort, turned to powerful outside help. It spent $2.4 million on lobbyists that year, according to OpenSecrets.org. Among the Amgen representatives were Haley Barbour, the former chairman of the Republican National Committee, and C. Boyden Gray, formerly White House counsel to George H.W. Bush.
Amgen lobbying expenditures and political efforts jumped that year. The company ranked as the largest contributor to the campaign of House Speaker Nancy Pelosi (D-Calif.), which got $42,050.
Amid the campaign, Reps. Anna G. Eshoo (D-Calif.) and Mike Rogers (R-Mich.) drafted a letter to Medicare, signed by a majority in both houses, warning that the proposed Medicare limits on the drugs could have a broad range of unintended health consequences.